Dolcontin

Quick links to important sections

Dolcontin

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dolcontin

What is Dolcontin? Overview

Property Description
Active Ingredient Morphine Sulfate
Form Extended-Release Tablet (Oral)
Pharmacological Class Opioid Analgesic
Prescription Status Prescription Only (Rx)
Origin Derived from the Opium Poppy (Opiate)

What Type of Medication is Dolcontin? (Identity and Classification)

Dolcontin is a specific brand of medication that contains the active ingredient morphine sulfate, and is classified pharmacologically as a potent opioid analgesic. It is an oral, extended-release tablet and requires a prescription (Rx) for use.

Unlike immediate-release versions of its active compound, the distinctive feature of the Dolcontin formulation is its controlled-release mechanism. This design is clinically recognized for providing steady pain relief over many hours, which is a necessity for the continuous management of persistent symptoms. This sustained-release profile differentiates it from short-acting opioids, which are reserved for rapid, temporary pain relief.

What is the General Therapeutic Purpose of Dolcontin? (The "Why")

The primary therapeutic purpose of Dolcontin is to manage severe, persistent chronic pain that requires daily, around-the-clock opioid treatment for an extended duration. This medication is intended for long-term pain control when other alternative treatments are insufficient.

The extended-release nature means it serves as a foundational treatment to maintain a stable level of comfort. It is used as part of a treatment plan for patients whose pain is significant enough that the benefits of consistent, long-term therapy are deemed necessary to improve quality of life.

What side effects are possible with Dolcontin?

Possible side effects and safety information

Dolcontin, which contains morphine sulfate, has a documented safety profile consistent with its classification as a potent opioid analgesic. Official regulatory documents define the spectrum of possible adverse reactions, categorize their frequency, and highlight significant safety concerns.

Critical Safety Warnings and Serious Adverse Reactions

The most critical safety concern documented in regulatory labeling is the risk of life-threatening or fatal respiratory depression. This serious adverse reaction poses the highest risk during the initiation of treatment and following any dosage increase. Additionally, the medication carries documented risks of addiction, abuse, and misuse.

Serious adverse reactions also include the potential for Severe Hypotension and risks associated with use alongside other central nervous system depressants, which can lead to profound sedation, coma, and death. Use during pregnancy can result in the Neonatal Opioid Withdrawal Syndrome (NOWS) in the newborn. The medication is contraindicated in the presence of significant respiratory depression or gastrointestinal obstruction, such as paralytic ileus.

Common Adverse Reactions and Systemic Effects

Adverse reactions classified as most common or frequently observed upon the start of therapy often involve the gastrointestinal and nervous systems:

  • Gastrointestinal Disorders: Constipation, Nausea, and Vomiting.
  • Nervous System Disorders: Somnolence (sleepiness/drowsiness), Sedation, Dizziness, and Lightheadedness.
  • Skin and Subcutaneous Tissue Disorders: Sweating.

Population-Specific Safety Notes

The official label highlights increased safety risks for specific groups. Elderly and debilitated patients are recognized as having an increased risk for respiratory depression. Caution and monitoring are also specified for individuals with severe renal or hepatic impairment.

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

Overdose of Dolcontin (Morphine Sulfate Extended-Release) is defined in regulatory documents by its potential for life-threatening effects on the central nervous and respiratory systems. Documented clinical manifestations include profound sedation progressing to unresponsiveness or coma, and respiratory depression marked by slow, shallow, or arrested breathing (apnea). Additional signs may involve miosis (pinpoint pupils), hypotension (low blood pressure), and cyanosis (bluish skin discoloration) due to low oxygen levels. Severe outcomes officially cited include circulatory shock, respiratory arrest, and the risk of a fatal overdose.

When to Seek Immediate Medical Help

Regulatory guidance explicitly mandates to seek immediate medical help or emergency assistance (e.g., calling 911) if overdose is suspected or if any severe symptoms, such as difficulty breathing or profound sedation, are observed. Do not delay calling for assistance.

Management and Specific Warnings

The official management approach involves symptomatic and supportive treatment and the administration of Naloxone, the documented opioid antagonist. Due to the extended-release nature, prolonged monitoring in a medical setting is required. Regulatory sources issue a specific warning that the accidental ingestion of even one dose can be fatal, particularly in children or individuals not tolerant to opioids. Elderly or debilitated patients are noted to have an increased susceptibility to severe respiratory depression.

Therapeutic Uses of Dolcontin

What Dolcontin Treats: Main Uses and Benefits

Dolcontin is used for managing severe and persistent pain in conditions that may require long-term, around-the-clock supportive relief, in situations when symptoms related to physical discomfort cannot be managed by other supportive therapies. The medication is applied in situations involving distressing symptoms associated with advanced diseases, such as cancer pain, and is applicable within clinical settings that involve heightened systemic burden associated with advanced conditions.


Therapeutic Scope

This medication is commonly considered for symptoms related to physical discomfort classified as severe. It contributes to sustained pain relief, offering foundational support that helps maintain a patient’s comfort level. The medication is applied in addressing symptom clusters that may become intense or disruptive, such as persistent pain and chronic discomfort, and may assist with severe, chronic breathlessness (dyspnea).

“This continuous, stable effect assists with maintaining functional stability and supports patients during episodes of heightened discomfort.”


Quick Fact: Symptomatic Support

Quick Fact: Symptomatic Support

This extended-release formulation provides supportive relief when severe symptoms interfere with routine activities, contributing to a stable, continuous therapeutic effect throughout the day and night.

Regulatory References

  1. DailyMed FDA Labeling

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Dolcontin — official regulatory information

Populations for whom use is allowed (as stated in label):

  • Adult patients with severe and persistent chronic pain requiring daily, around-the-clock opioid treatment.
  • For high-strength doses, patients must be opioid-tolerant.

Populations for whom use is contraindicated:

  • Individuals with significant respiratory depression or acute, severe bronchial asthma in an unmonitored setting.
  • Patients with known or suspected gastrointestinal obstruction, including paralytic ileus.
  • Use is prohibited with or within 14 days of taking Monoamine Oxidase Inhibitors (MAOIs), or in case of hypersensitivity to morphine.

Age and Condition-specific eligibility rules:

  • Pediatric Use: Safety and effectiveness of the extended-release formulation have not been established in pediatric patients.
  • Geriatric Use: Elderly patients are at an increased risk of serious adverse effects, including respiratory depression, and require close monitoring.
  • Renal/Hepatic Impairment: Patients with impaired renal or hepatic function are eligible for use but must be managed with caution and close monitoring due to the risk of accumulation.

Pregnancy and lactation eligibility status:

  • Pregnancy: Long-term use carries the regulatory risk of Neonatal Opioid Withdrawal Syndrome.
  • Lactation: Use is not recommended due to the presence of morphine in breast milk and the risk to the infant.

Connection to the overall eligibility profile: The regulatory documents establish that Dolcontin is intended exclusively for adults with severe, chronic pain who meet specific safety prerequisites and are free from absolute prohibitions like severe respiratory dysfunction or gastrointestinal obstruction. Eligibility in sensitive populations, such as the elderly, organ-impaired, and pregnant or nursing women, is defined by special caution, restriction, or non-recommendation.

What should I know about interactions with other medicines?

Dolcontin’s interaction profile is strictly defined by government regulatory documentation, establishing combinations that are prohibited or require extreme caution due to altered drug effects or concentrations.

Contraindicated Combinations and Timing Rules

The use of Dolcontin is formally contraindicated with Monoamine Oxidase Inhibitors (MAOIs). This combination is prohibited, and treatment must not begin within 14 days of discontinuing an MAOI, representing a mandatory, time-based interaction constraint.

Pharmacodynamic Interaction Risks

Co-administration with Central Nervous System (CNS) Depressants, including benzodiazepines, carries a major pharmacodynamic risk. This combination may result in additive depressant effects, leading to profound sedation, respiratory depression, coma, and death. Concurrent use with Serotonergic Drugs is documented to potentially result in Serotonin Syndrome. Using Mixed Agonist/Antagonist Opioids is restricted as it may reduce the analgesic effect or precipitate withdrawal symptoms.

Exposure Modification and Substance Restrictions

The co-ingestion of alcoholic beverages or products containing alcohol must be strictly avoided. This substance interaction causes a rapid release and increased absorption of morphine, leading to a dangerous increase in plasma concentration. Morphine is also a substrate for P-glycoprotein (P-gp), and co-administration with P-gp inhibitors may increase the active ingredient's plasma concentration. Official labeling notes that elderly, cachectic, or debilitated patients have a greater risk for respiratory depression from CNS depressant interactions.

Mechanism of Action

Dolcontin (morphine) acts centrally within the Central Nervous System (CNS) and peripherally by targeting opioid receptors. Its primary biological target is the mu-opioid receptor ( MOR), where it functions as a receptor agonist.

Binding of the drug to the MOR, a G protein-coupled receptor (GPCR), stimulates the exchange of GDP for GTP on the inhibitory Gi protein complex. The activated Gi subunit then dissociates, leading to two key intracellular consequences:

  1. Inhibition of adenylate cyclase ( AC), which decreases the intracellular concentration of the second messenger cyclic AMP ( cAMP). This reduction in cAMP modulates protein phosphorylation.
  2. Activation of inwardly-rectifying potassium channels and inhibition of N-type voltage-operated calcium channels on presynaptic neurons.

The resulting efflux of potassium ions hyperpolarizes the postsynaptic membrane, decreasing neuronal excitability. The inhibition of calcium influx into the presynaptic terminal reduces the release of excitatory neurotransmitters, such as Substance P and glutamate, from nociceptive afferent fibers. This dual action modulates system-level physiological responses by inhibiting the transmission of afferent nociceptive signals in the spinal cord and altering perception in the brain.

Dosage and Administration Information

How to Use Dolcontin

The extended-release formulation of Dolcontin (morphine sulfate) is intended for management requiring daily, around-the-clock, long-term treatment and is not indicated for as-needed (prn) use.


Official Administration Guidelines

Instruction Entity General Administration Statement
Route of administration Oral (via swallowing the intact tablet).
Dosing schedule Treatment for opioid-naïve patients is initiated with 15 mg tablets orally every 8 to 12 hours. Doses are subsequently adjusted every 1 to 2 days to achieve individualized, continuous pain control.
Timing in relation to meals The tablet may be taken with or without food.
Preparation requirements The tablets must be swallowed whole. They are not to be cut, crushed, chewed, or dissolved, as this action compromises the controlled-release mechanism.
Age-group rules Caution is advised for use in older adults due to the potential for decreased renal or hepatic function.
Discontinuation The medication must not be abruptly discontinued in a physically dependent patient. Discontinuation requires a gradual, patient-specific, downward titration (tapering) regimen.

Procedural Structure for Use

The formal administration protocol is defined by a fixed schedule and strict consumption rules. The initial regimen starts with the lowest available extended-release dose, which is systematically increased every few days to reach the maintenance dose required for stable relief. Throughout the treatment period, the tablet must be administered orally and swallowed intact to ensure the slow, controlled absorption of the active ingredient. Upon conclusion of long-term use, the dose must be slowly reduced according to a planned taper to mitigate physical dependence symptoms.

Recent Clinical Evidence

Clinical Evidence Overview

Research regarding Dolcontin, a brand name for morphine sulfate extended-release, primarily focuses on its use for managing severe and persistent pain that necessitates around-the-clock opioid treatment. These extended-release formulations are not intended for short-term, mild, or as-needed pain relief.


Core Efficacy Studies

A large number of randomized, placebo-controlled trials (RCTs) have been conducted to investigate the effectiveness of extended-release opioids, including morphine, for chronic non-cancer pain. Taken together, these studies provide evidence that opioid treatment may be associated with statistically significant improvements in pain intensity and physical functioning over study durations typically lasting up to 12 weeks.

  • Phase III Trial Findings: Trials evaluating extended-release morphine formulations often use an enriched-enrollment withdrawal design. This method identifies participants who initially respond well to the medication, and then randomizes them to continue the drug or switch to a placebo. These trials examine whether those who continue treatment maintain their pain relief compared to those switched to placebo.

Long-Term Research and Special Populations

Studies have explored the persistence of analgesic outcomes over longer periods, with some open-label extension studies following participants for up to one year. These observational data examine whether a cohort of participants can maintain stable pain relief over extended treatment.

Research has also explored the effects of extended-release morphine in specific populations, such as older adults with persistent, moderate-to-severe pain. Findings from subgroup analyses of these studies suggest that older patients who completed the study may attain improvements in pain, sleep, and quality of life scores.

Frequently Asked Questions (FAQ)

Common questions about Dolcontin (FAQ)


Q: How long does a dose of Dolcontin last for pain relief?

Official product information indicates that the extended-release tablet is typically administered every 8 to 12 hours. This schedule is necessary to provide continuous, around-the-clock pain relief, which is the intended therapeutic goal of the medication.


Q: Does Dolcontin start working immediately?

No. Regulatory documents state that this medication is not indicated for as-needed (prn) use, nor is it intended for pain that is mild. The controlled-release design is intended to release the medication slowly, providing a stable, sustained effect over time, rather than rapid, immediate relief.


Q: Do all people experience constipation when taking Dolcontin?

No, not all people experience this side effect. However, according to the official product information, constipation is listed as one of the most common or frequently observed adverse reactions. Patients are often advised to discuss strategies for managing this common side effect with their healthcare provider.


Q: Can Dolcontin interact with common over-the-counter cold medicines?

Official labeling advises caution when combining Dolcontin with other drugs that cause Central Nervous System (CNS) depression. Many common cold medicines can have CNS effects. Combining it with other CNS depressants may increase the risk of serious adverse effects, such as profound sedation or breathing difficulties.


Q: Does Dolcontin interact with antidepressants or anxiety medications?

Yes. Official regulatory documents indicate that combining Dolcontin with CNS depressants (like some anxiety medications) or Serotonergic Drugs (like some antidepressants) can increase the risk of severe adverse effects. These risks include profound sedation, respiratory depression, or the development of Serotonin Syndrome.


Q: Can Dolcontin be used for breakthrough pain?

No. Official labeling states that the extended-release formulation is not for use as an as-needed (prn) analgesic. Its purpose is to provide a steady, consistent level of pain relief for severe, persistent pain, and its use is reserved for continuous, around-the-clock pain management.


Q: Can Dolcontin show up on drug tests?

Yes. The active ingredient in Dolcontin is morphine, a potent opioid analgesic. As the active ingredient is morphine, a potent opioid, its use can result in a positive test for opiates.


Q: Can Dolcontin be used for nerve pain?

Official indications state that this medication is for the management of severe and persistent chronic pain that requires around-the-clock opioid treatment. It is not specifically limited to or excluded from use for nerve pain, but it is used as part of a pain management strategy.


Q: Are there any long-term side effects associated with Dolcontin use?

Yes. Regulatory documents highlight serious long-term risks, which are emphasized by official warnings, including risks related to Addiction, Abuse, and Misuse. Chronic opioid use may also be associated with hormonal issues such as Adrenal Insufficiency and Hypogonadism (a type of hormone imbalance).


Q: Can Dolcontin cause changes in mood or sleep?

Yes. Common adverse reactions listed in official documents include sedation and somnolence (sleepiness or drowsiness). As the medication acts on the Central Nervous System, changes in mood and an impact on sleep patterns are possible.


Q: How should I store Dolcontin safely at home?

Official guidelines require that this medication be stored securely at room temperature, away from excessive moisture and heat. Because it is a controlled substance, it should be kept in a locked cabinet or safe, strictly out of the sight and reach of children and pets, to prevent accidental exposure or misuse.


Q: Are there any foods or supplements that should be avoided when taking Dolcontin?

Yes. Alcoholic beverages or products containing alcohol must be strictly avoided as this can cause a dangerous, rapid release and absorption of the drug. Caution is also advised when combining with certain dietary supplements as they can sometimes interfere with drug metabolism.


Q: Why do doctors recommend a specific schedule for taking Dolcontin?

The fixed dosing schedule (e.g., every 8 or 12 hours) is required because this is an extended-release formulation. The purpose is to provide a continuous, around-the-clock level of medication in the bloodstream to maintain stable pain relief and prevent the pain from returning between doses.


Q: Is there a maximum dose of Dolcontin a person can take in a day?

Official labeling does not specify a single absolute "maximum dose" for all patients. Instead, the dose is always determined individually by a healthcare provider. The highest strength tablets are reserved only for patients who are considered opioid-tolerant, reflecting the need for individualized dosing decisions.


Q: How quickly can the body build a tolerance to Dolcontin?

Regulatory documents acknowledge the development of tolerance (the need for a higher dose to achieve the same effect) as a risk associated with chronic opioid use. However, the official information does not provide a specific timeline for how quickly tolerance may develop in an individual patient.


Q: What should I do if I think I'm experiencing a severe side effect from Dolcontin?

Official guidelines recommend contacting a healthcare provider or seeking emergency medical help immediately. This is particularly important if signs of severe side effects are suspected, such as life-threatening respiratory depression (slow or shallow breathing), extreme sleepiness, or difficulty waking up.


Q: Is it possible for Dolcontin to cause excessive sweating?

Yes. According to official documents, sweating is listed as one of the most common adverse reactions reported by patients.


Q: Are there any known drug-disease interactions with Dolcontin?

Yes. The medication is not recommended or is contraindicated for people with certain conditions, such as significant respiratory depression or gastrointestinal obstruction. Caution is also required for patients with conditions like adrenal insufficiency or severe renal (kidney) or hepatic (liver) impairment.


Q: Has the formulation of Dolcontin changed over the years?

While the active ingredient, morphine, has remained the same, regulatory bodies have required major safety labeling changes for all opioid pain medications. These changes emphasize and explain the serious risks of addiction and misuse.


Q: Do different brands of extended-release morphine work the same as Dolcontin?

In many countries, regulatory bodies consider generic versions of extended-release morphine (the active ingredient in Dolcontin) to be therapeutically equivalent. Generic products are often considered to be interchangeable, provided they meet strict government bioequivalence standards.


Q: Is there a non-addictive component in Dolcontin?

No. Dolcontin is a single-component drug containing only the active ingredient morphine sulfate, which is classified as a potent opioid agonist.


Q: Why is it important to take Dolcontin exactly as prescribed, even if pain is controlled?

Taking the medication exactly as prescribed is critical to managing the risks of addiction, abuse, and misuse. For patients who may be physically dependent, stopping the medication abruptly is strongly advised against, as it must be reduced gradually according to a specific plan.


Q: Are there any natural remedies that can help with Dolcontin side effects?

Yes. For the common side effect of constipation, official health authority information, such as from the NIH, mentions non-pharmacological methods. These generally include increasing dietary fiber, ensuring adequate fluid intake, and engaging in appropriate physical exercise.


Q: What is the role of Naloxone in reducing risks associated with medications like Dolcontin?

Regulatory agencies advise discussing the availability of Naloxone with the patient and caregiver. Naloxone is a medication that works to reverse the effects of an opioid overdose, particularly life-threatening respiratory depression, by temporarily binding to the opioid receptors.

How should Dolcontin be stored and disposed of?

How to Store and Dispose of Dolcontin?

Dolcontin (morphine extended-release) must be stored and disposed of according to strict official guidelines due to its controlled substance classification.

Storage and Handling

To maintain the medicine's quality, store it securely at room temperature, away from excessive moisture and heat, and strictly out of the sight and reach of children and pets. As a controlled substance, it must be kept in a locked cabinet or safe at all times to prevent theft, misuse, or accidental exposure, which can be fatal.

Disposal Requirements

Official regulatory documents state that the best method for disposal is to use an authorized drug take-back program or a mail-back envelope. If these options are not readily available, specific instructions for safe disposal in household trash must be followed. This typically involves mixing the medicine with an unappealing substance like used coffee grounds or dirt, sealing it in a plastic bag, and discarding it.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dolcontin found in:

A-Z Index: